Generic Xolremdi Availability
Last updated on May 7, 2025.
Xolremdi is a brand name of mavorixafor, approved by the FDA in the following formulation(s):
XOLREMDI (mavorixafor - capsule;oral)
-
Manufacturer: X4 PHARMS
Approval date: April 26, 2024
Strength(s): 100MG [RLD]
Is there a generic version of Xolremdi available?
No. There is currently no therapeutically equivalent version of Xolremdi available in the United States.
Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Xolremdi. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.
See also: Generic Drug FAQ.
Related patents
Patents are granted by the U.S. Patent and Trademark Office at any time during a drug's development and may include a wide range of claims.
-
Compositions of CXCR4 inhibitors and methods of preparation and use
Patent 10,548,889
Issued: February 4, 2020
Inventor(s): Brands Karel Marie Joseph
Assignee(s): X4 PHARMACEUTICALS, INC.The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Patent expiration dates:
- December 11, 2038✓
- December 11, 2038
-
Methods for treating immunodeficiency disease
Patent 10,610,527
Issued: April 7, 2020
Inventor(s): Arbeit Robert D. & Ragan Paula Marie
Assignee(s): X4 PHARMACEUTICALS, INC.The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.
Patent expiration dates:
- December 22, 2036✓
- December 22, 2036
-
Methods for treating cancer
Patent 10,953,003
Issued: March 23, 2021
Inventor(s): Ragan; Paula Marie et al.
Assignee(s): X4 PHARMACEUTICALS, INC. (Cambridge, MA); GENZYME CORP. (Cambridge, MA)The present invention relates to methods of treating patients with advanced forms of cancer, such as clear cell renal cell carcinoma, in which X4P-001 is administered in order to reduce angiogenic escape that typically occurs with TKI therapy. The methods demonstrate surprising results, including regression of tumor size and cell number, with comparatively little toxicity.
Patent expiration dates:
- December 14, 2036✓
- December 14, 2036
-
Compositions of CXCR4 inhibitors and methods of preparation and use
Patent 11,045,461
Issued: June 29, 2021
Inventor(s): Brands Karel Marie Joseph
Assignee(s): X4 PHARMACEUTICALS, INC.The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Patent expiration dates:
- December 11, 2038✓
- December 11, 2038
-
Methods for treating immunodeficiency disease
Patent 11,219,621
Issued: January 11, 2022
Inventor(s): Arbeit Robert D. & Ragan Paula Marie
Assignee(s): X4 Pharmaceuticals, Inc.The present invention relates to methods of treating patients with WHIM syndrome or related disorders, such as myelokathexis, in which X4P-001 is administered in order to reduce the activity of CXCR4. The methods demonstrate surprising effectiveness, with comparatively little toxicity.
Patent expiration dates:
- December 22, 2036✓
- December 22, 2036
-
Compositions of CXCR4 inhibitors and methods of preparation and use
Patent 12,115,156
Issued: October 15, 2024
Inventor(s): Brands; Karel Marie Joseph
Assignee(s): X4 Pharmaceuticals, Inc. (Boston, MA)The present invention provides compositions and methods of use for treating, preventing, or ameliorating a disease, disorder, or condition associated with a chemokine receptor such as CXCR4.
Patent expiration dates:
- December 11, 2038✓
- December 11, 2038
Related exclusivities
Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.
Exclusivity expiration dates:
- April 26, 2029 - NEW CHEMICAL ENTITY
- April 26, 2031 - TO INCREASE THE NUMBER OF CIRCULATING MATURE NEUTROPHILS AND LYMPHOCYTES IN PATIENTS 12 YEARS OF AGE AND OLDER WITH WHIM SYNDROME (WARTS, HYPOGAMMAGLOBULINEMIA, INFECTIONS AND MYELOKATHEXIS)
More about Xolremdi (mavorixafor)
- Check interactions
- Compare alternatives
- Pricing & coupons
- Drug images
- Side effects
- Dosage information
- During pregnancy
- FDA approval history
- Drug class: other immunostimulants
- Breastfeeding
- En español
Patient resources
Professional resources
Related treatment guides
Glossary
| Term | Definition |
|---|---|
| Drug Patent | A drug patent is assigned by the U.S. Patent and Trademark Office and assigns exclusive legal right to the patent holder to protect the proprietary chemical formulation. The patent assigns exclusive legal right to the inventor or patent holder, and may include entities such as the drug brand name, trademark, product dosage form, ingredient formulation, or manufacturing process A patent usually expires 20 years from the date of filing, but can be variable based on many factors, including development of new formulations of the original chemical, and patent infringement litigation. |
| Drug Exclusivity | Exclusivity is the sole marketing rights granted by the FDA to a manufacturer upon the approval of a drug and may run simultaneously with a patent. Exclusivity periods can run from 180 days to seven years depending upon the circumstance of the exclusivity grant. |
| RLD | A Reference Listed Drug (RLD) is an approved drug product to which new generic versions are compared to show that they are bioequivalent. A drug company seeking approval to market a generic equivalent must refer to the Reference Listed Drug in its Abbreviated New Drug Application (ANDA). By designating a single reference listed drug as the standard to which all generic versions must be shown to be bioequivalent, FDA hopes to avoid possible significant variations among generic drugs and their brand name counterpart. |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
